Healthcare ❯Pharmaceuticals

Weight Loss Drugs

Ozempic Wegovy Zepbound Novo Nordisk GLP-1 Agonists Mounjaro Tirzepatide GLP-1 Drugs GLP-1 Receptor Agonists GLP-1s Semaglutide Incretin Drugs Survodutide GLP-1 Medications Amycretin Tirzepatide (Zepbound) Challenges Approval and Availability Financial Barriers Cost Reduction and Access Petrelintide Clinical Trials Tirzepatide vs. Semaglutide Comparison Clinical Studies Market Availability Market Trends Cost Barriers Effectiveness Studies Prescription Medications GLP Inhibitors Insurance Coverage Obesity Treatments

Poll Shows Americans Divided Over Weight-Loss Drugs for Obesity Treatment

U.S. Obesity Rates Decline for First Time in Over a Decade

Expanded Access to Weight-Loss Drugs Could Save Over 40,000 Lives Annually

Senator Warren Urges FTC to Scrutinize Novo Holdings' $16.5B Catalent Acquisition

Eli Lilly's Weight-Loss Drugs Drive Record Q2 Revenue Surge

Ozempic Shows Promise Beyond Diabetes Treatment

Eli Lilly's Mounjaro Outperforms Novo Nordisk's Ozempic in Weight Loss Study

Weight-Loss Drug Tirzepatide Shows Promise for Treating Sleep Apnea

Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

Weight-Loss Drug Market Heats Up as Prices Drop and New Treatments Emerge

Eli Lilly's Q1 Earnings Surge on Strong Zepbound and Mounjaro Sales

Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients

Wegovy Approved for Heart Health, Faces Insurance Coverage Challenges

Eli Lilly and Amazon Partner to Deliver Weight Loss Drug Zepbound Directly to Consumers

Novo Nordisk's Amycretin Shows Promise as Next-Gen Weight Loss Drug